HK51997A - Substituted -1,3-oxathiolanes with antiviral properties - Google Patents

Substituted -1,3-oxathiolanes with antiviral properties

Info

Publication number
HK51997A
HK51997A HK51997A HK51997A HK51997A HK 51997 A HK51997 A HK 51997A HK 51997 A HK51997 A HK 51997A HK 51997 A HK51997 A HK 51997A HK 51997 A HK51997 A HK 51997A
Authority
HK
Hong Kong
Prior art keywords
oxathiolanes
substituted
antiviral properties
antiviral
properties
Prior art date
Application number
HK51997A
Other languages
English (en)
Inventor
Bernard Belleau
Pierette Belleau
Nghe Nguyen-Ba
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25678044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK51997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA002152269A external-priority patent/CA2152269C/en
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of HK51997A publication Critical patent/HK51997A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
HK51997A 1989-02-08 1997-04-24 Substituted -1,3-oxathiolanes with antiviral properties HK51997A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/308,101 US5047407A (en) 1989-02-08 1989-02-08 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CA002152269A CA2152269C (en) 1989-02-08 1992-12-21 Process for preparing substituted 1,3-oxathiolanes with antiviral properties

Publications (1)

Publication Number Publication Date
HK51997A true HK51997A (en) 1997-05-02

Family

ID=25678044

Family Applications (2)

Application Number Title Priority Date Filing Date
HK51997A HK51997A (en) 1989-02-08 1997-04-24 Substituted -1,3-oxathiolanes with antiviral properties
HK98109873A HK1009270A1 (en) 1989-02-08 1998-08-12 Substituted-1,3-oxathiolanes with antiviral properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK98109873A HK1009270A1 (en) 1989-02-08 1998-08-12 Substituted-1,3-oxathiolanes with antiviral properties

Country Status (35)

Country Link
US (1) US5047407A (ja)
EP (2) EP0711771B1 (ja)
JP (4) JP2644357B2 (ja)
KR (1) KR960007531B1 (ja)
CN (1) CN1033640C (ja)
AP (1) AP136A (ja)
AT (2) ATE254125T1 (ja)
AU (1) AU630913B2 (ja)
CA (1) CA2009637C (ja)
CY (1) CY2036A (ja)
CZ (1) CZ282720B6 (ja)
DE (3) DE19675032I2 (ja)
DK (2) DK0711771T3 (ja)
ES (2) ES2206476T3 (ja)
FI (1) FI98065C (ja)
GR (1) GR3019919T3 (ja)
HK (2) HK51997A (ja)
HR (1) HRP940040B1 (ja)
HU (2) HU208134B (ja)
IE (1) IE72184B1 (ja)
IL (1) IL93318A (ja)
LU (1) LU88809I2 (ja)
MX (1) MX19437A (ja)
NL (1) NL960025I2 (ja)
NO (2) NO179518C (ja)
NZ (1) NZ232421A (ja)
OA (1) OA09193A (ja)
PL (1) PL164785B1 (ja)
PT (1) PT93094B (ja)
RU (1) RU2092485C1 (ja)
SG (2) SG77215A1 (ja)
SI (1) SI9010243B (ja)
SK (1) SK279175B6 (ja)
YU (1) YU48840B (ja)
ZA (1) ZA90943B (ja)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
ATE237613T1 (de) * 1989-02-08 2003-05-15 Iaf Biochem Int Verfahren für die herstellung von antiviralen substituierten 1, 3-oxathiolanen
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
CA2095613C (en) * 1990-11-13 2001-01-02 Bernard Belleau Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
IL101144A (en) * 1991-03-06 1996-09-12 Wellcome Found Pharmaceutical preparations containing 1 -) 2 -) hydroxymethyl (- 1, 3 - oxathiolan-5 - il (5) fluorescitosin and its derivatives for the treatment of their hepatitis B virus infections
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
EP0513917B2 (en) * 1991-05-16 2001-03-07 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
DK0530407T3 (da) * 1991-09-04 1996-07-29 Stichting Rega V Z W Substituerede nukleosidderivater, fremgangsmåder til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
JPH09504785A (ja) * 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
WO1996031217A1 (en) * 1995-04-04 1996-10-10 Duke University Inhibiting retroviral replication
WO1996040164A1 (en) 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
FR2746396B1 (fr) * 1996-03-20 1998-06-05 Inst Nat Sante Rech Med 1,3-thiazolidin-4-ones et 1,3-thiazolidines substituees, procede d'obtention de ces composes et leurs utilisations comme medicaments
PL330747A1 (en) 1996-06-25 1999-05-24 Glaxo Group Ltd Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US20040044016A1 (en) * 1997-01-31 2004-03-04 Mitsubishi Chemical Corporation Antiviral agents
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
IT1290447B1 (it) 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
EP2390257A1 (en) 1998-02-25 2011-11-30 Emory University 2'-fluoronucleosides
AU771779B2 (en) 1998-08-12 2004-04-01 Emory University Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ES2314157T3 (es) 1998-11-02 2009-03-16 Gilead Sciences, Inc. Terapia de combinacion para tratar el virus de la hepatitis b.
CA2348470C (en) 1998-11-05 2007-06-05 Centre National De La Recherche Scientifique Nucleosides with anti-hepatitis b virus activity
DK1140937T3 (da) 1998-12-23 2004-03-22 Shire Biochem Inc Antivirale nucleosid-analoger
BR0009378A (pt) * 1999-03-29 2002-01-08 Shire Biochem Inc Métodos de tratamento de leucemia
WO2000071539A1 (en) * 1999-05-26 2000-11-30 Pharm-Eco Laboratories Inc. Methods of separating ftc isomers and derivatives thereof
US6752929B1 (en) * 1999-05-26 2004-06-22 Johnson Matthey Pharmaceutical Materials, Inc. Methods of separating FTC isomers and derivatives thereof
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
TR200601784T2 (tr) * 1999-11-12 2007-01-22 Pharmasset Ltd. 2'-deoksi-L-nükleositlerin sentezi
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
GB0016845D0 (en) * 2000-07-07 2000-08-30 Leuven K U Res & Dev Pharmaceutical composition for treatment of HIV infection
WO2002051852A1 (fr) * 2000-12-27 2002-07-04 Mitsui Chemicals, Inc. Procede de production d'un derive de saccharide non naturel
KR101150250B1 (ko) 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
GEP20063848B (en) * 2001-10-26 2006-06-12 Inst Di Richerche Di Biolog Moltcolare P Angeletti Spa N-substituted hydroxypyrimi-dinone carboxamide inhibitors of hiv integrase
AU2002364160A1 (en) * 2001-12-14 2003-06-30 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
CA2494183C (en) 2002-08-06 2012-01-03 Kyoichi A. Watanabe Processes for preparing 1,3-dioxolane nucleosides
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
WO2004043433A2 (en) * 2002-11-08 2004-05-27 Glaxo Group Limited Pharmaceutical antiviral compositions
WO2004052296A2 (en) * 2002-12-09 2004-06-24 The University Of Georgia Research Foundation, Inc. Dioxolane thymine and combinations for use against 3tc/ azt resistant strains of hiv
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
JP2006214695A (ja) * 2005-02-07 2006-08-17 Sanken Setsubi Kogyo Co Ltd 空調システム
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
KR20080053317A (ko) * 2005-08-31 2008-06-12 씨아이피엘에이 엘티디. 라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물
CN1328240C (zh) * 2005-08-31 2007-07-25 四川大学 苯甲酰氧基乙醛的制备方法
NZ567272A (en) 2005-09-26 2012-02-24 Pharmasset Inc Modified 4'-nucleosides as antiviral agents
AP2008004533A0 (en) * 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007119248A1 (en) * 2006-04-18 2007-10-25 Lupin Limited A novel crystalline form of lamivudine
US20110257396A1 (en) * 2006-10-30 2011-10-20 Lupin Limited Process for the manufacture of cis(-)-lamivudine
KR100840495B1 (ko) 2007-04-13 2008-06-23 한미약품 주식회사 라미부딘을 입체선택적으로 제조하는 방법
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
CN101918416A (zh) * 2007-11-29 2010-12-15 兰贝克赛实验室有限公司 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体
WO2009069011A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
CA2706018C (en) * 2007-11-30 2015-11-24 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
NZ612380A (en) 2008-12-09 2015-01-30 Gilead Sciences Inc Modulators of toll-like receptors
WO2010082128A1 (en) 2009-01-19 2010-07-22 Aurobindo Pharma Limited Process for the preparation of cis-nucleoside derivative
EP2414363B1 (en) * 2009-03-31 2014-01-08 Boehringer Ingelheim International GmbH 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
KR101474570B1 (ko) 2009-04-13 2014-12-19 주식회사 대희화학 라미부딘의 신규한 중간체 및 이의 제조방법
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
ES2540074T3 (es) 2009-10-14 2015-07-08 Mylan Laboratories Limited Proceso para la preparación de lamivudina y nuevas sales en la fabricación de la misma
RS54123B1 (en) 2010-01-27 2015-12-31 Viiv Healthcare Company THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
WO2011095987A1 (en) 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CN102234269B (zh) * 2010-04-29 2015-09-16 重庆医药工业研究院有限责任公司 拉米夫定的工业化制备方法
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
DK2603511T3 (en) 2010-08-12 2017-05-08 Boehringer Ingelheim Int 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO- [3,4-D] PYRIMIDIN-4-ON DERIVATIVES AND THEIR USES AS PDE9A INHIBITORS
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2739620A1 (en) 2011-08-05 2014-06-11 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN103694231A (zh) * 2013-11-28 2014-04-02 安徽一帆香料有限公司 一种拉米夫定中间体hdms的合成制备方法
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN113577081A (zh) 2014-07-11 2021-11-02 吉利德科学公司 用于治疗hiv的toll样受体调节剂
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
WO2017095761A1 (en) 2015-12-02 2017-06-08 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2018178722A1 (en) * 2017-03-31 2018-10-04 The University Of Liverpool Prodrug compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (ja) * 1976-08-09 1985-10-08 株式会社興人 １−（２−テトラヒドロフリル）ウラシル類の製造方法
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS56167685A (en) * 1980-05-28 1981-12-23 Taiho Yakuhin Kogyo Kk 1- 2-tetrahydrothiophene-1,1-dioxide -5-fluorouracil and its preparation
JPS56169689A (en) * 1980-06-02 1981-12-26 Taiho Yakuhin Kogyo Kk 3-substituted-5-fluorouracil derivative and its preparation
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
SU1035023A1 (ru) * 1982-03-23 1983-08-15 Ордена Трудового Красного Знамени Институт Органической И Физической Химии Им.А.Е.Арбузова Способ получени 3-(тииранил-2-метил)-6-метилурацилов
DE3324769A1 (de) * 1983-07-08 1985-01-17 Bayer Ag, 5090 Leverkusen 5-aminomethyl-1,3-oxathiolane
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
CA1312599C (en) * 1988-02-16 1993-01-12 Larry Wayne Hertel 2',3'dideoxy-2',2'difluoronucleosides
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds

Also Published As

Publication number Publication date
HU210537A9 (en) 1995-04-28
OA09193A (en) 1992-06-30
CY2036A (en) 1998-02-20
NO179518B (no) 1996-07-15
DE19675032I2 (de) 2007-11-08
EP0382526B1 (en) 1996-05-15
ATE254125T1 (de) 2003-11-15
IE72184B1 (en) 1997-03-26
ATE138065T1 (de) 1996-06-15
DE69034119D1 (de) 2003-12-18
IE900452L (en) 1990-08-08
AU4920190A (en) 1990-08-16
NO2001002I1 (no) 2001-02-12
MX19437A (es) 1993-05-01
SI9010243A (en) 1996-10-31
CZ282720B6 (cs) 1997-09-17
FI900631A0 (fi) 1990-02-08
JP2000143662A (ja) 2000-05-26
JPH08119967A (ja) 1996-05-14
JP3105154B2 (ja) 2000-10-30
CS410991A3 (en) 1992-07-15
HU900708D0 (en) 1990-04-28
NL960025I2 (nl) 1997-03-03
ZA90943B (en) 1990-10-31
EP0382526A3 (en) 1992-01-02
RU2092485C1 (ru) 1997-10-10
HU208134B (en) 1993-08-30
SG77215A1 (en) 2000-12-19
US5047407A (en) 1991-09-10
PL164785B1 (en) 1994-10-31
CN1044817A (zh) 1990-08-22
PT93094A (pt) 1990-08-31
IE960758L (en) 1990-08-08
HUT53362A (en) 1990-10-28
HK1009270A1 (en) 1999-05-28
CA2009637A1 (en) 1990-08-08
AP9000163A0 (en) 1990-04-30
EP0711771A2 (en) 1996-05-15
AU630913B2 (en) 1992-11-12
EP0382526A2 (en) 1990-08-16
JPH037282A (ja) 1991-01-14
NO900619L (no) 1990-08-09
JP2001226373A (ja) 2001-08-21
DE69026971T2 (de) 1996-09-12
KR900012932A (ko) 1990-09-03
DK0711771T3 (da) 2004-03-22
DE69034119T2 (de) 2004-08-26
YU48840B (sh) 2002-06-19
FI98065C (fi) 1997-04-10
NZ232421A (en) 1993-10-26
SK279175B6 (sk) 1998-07-08
CN1033640C (zh) 1996-12-25
FI98065B (fi) 1996-12-31
GR3019919T3 (en) 1996-08-31
IL93318A (en) 1995-07-31
LU88809I2 (fr) 1997-01-03
DK0382526T3 (da) 1996-08-05
NO900619D0 (no) 1990-02-08
EP0711771A3 (en) 1996-07-10
NO179518C (no) 2000-09-11
DE69026971D1 (de) 1996-06-20
EP0711771B1 (en) 2003-11-12
NL960025I1 (nl) 1997-01-06
KR960007531B1 (ko) 1996-06-05
HRP940040A2 (en) 1997-04-30
AP136A (en) 1991-08-05
PT93094B (pt) 1995-12-29
SG48737A1 (en) 1998-05-18
SI9010243B (sl) 1998-08-31
JP2644357B2 (ja) 1997-08-25
CA2009637C (en) 1997-10-07
ES2206476T3 (es) 2004-05-16
HRP940040B1 (en) 2002-04-30
YU24390A (en) 1991-10-31
ES2086371T3 (es) 1996-07-01

Similar Documents

Publication Publication Date Title
ZA90943B (en) Substituted-1,3-oxathiolanes with antiviral properties
MD809B2 (en) (-)-Enantiomer cis-4-amino-1-(2-hydroxymethil-1,3-oxathiolan-5-yl)-
GR3022463T3 (en) 1-H-3-aryl-pyrrolidin-2,4-dion-derivatives
GB2251034B (en) Shrouded aerofoils
DE68923951D1 (de) Hochgeschwindigkeits-Kombinierschalter mit Einzelfifo.
GB2265314B (en) Protective articles.
GB2228175B (en) Aseptically-packaged,aspartame-containing puddings
EG19674A (en) Antiviral tetrahydroimidazol (1,4) denzodiazepin -2-thiones
DE59000988D1 (en) Brueckenuntersichtvorrichtung.
HU896535D0 (en) 14alpha, 17alpha-etano-estratriene-derivatives
EP0515668A4 (en) Oxo-tetrahydropyridazinyl-pyrazolo 4,3-b)-1,4-benzoxazines
ZA903177B (en) N-sulfenyl-and n-sulfinyl-n,n'-diacylhydrazides
GB8911158D0 (en) Antiviral pyridazinamines
HU913371D0 (en) Substituted tieno(3,2-b)pyran-5,7-diones
DE58904224D1 (en) Thermobimetallmesswerk.
BA96097A (bs) Supstituirani 1,3-oksatiolani s antivirusnim svojstvima
IE893635L (en) 14ó,17ó-ethanoestratrienes
ZA909616B (en) 14alpha,17alpha-ethano-16alpha-hydroxy-estratrienes
GB9024371D0 (en) Putting,perceptor
IE900821L (en) 3-keto-16ó,17ó-dihydroxysteroids
HU896204D0 (en) Coloured, collapsible, plain toyfamily
IE880816L (en) 2',3'-dideoxynucleosides
HRP940041A2 (en) 1,3-oxathiolane nucleoside analogues
DE58904742D1 (en) Standfuss.
IE883828L (en) Acylating n, n-diallylanilines

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20100207